Dr. Aldo Calvo, Medical Director of Family Medicine at Broward Health, shows a Regeneron monoclonal antibody infusion bag during a news conference, Aug. 19, 2021, at the Hospital in Fort Lauderdale, Fla. As strained U.S. hospitals brace for a new surge of omicron COVID-19 cases, doctors are warning of yet another challenge: the two standard drugs they’ve used to treat early coronavirus infections are unlikely to work against the new variant. For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital. (Joe Cavaretta/South Florida Sun-Sentinel via AP) **FILE**
Featured Photo Galleries
